As evidenced by early studies of epidermal growth factor receptor (EGFR) inhibitors in lung cancer, the survival advantage from erlotinib and gefitinib was not demonstrated in clinical trials until predictive EGFR mutations were identified [24]. This evidence concerns the gene EGFR and lung carcinoma.